ANI Pharmaceuticals offers to acquire Egetis Therapeutics to expand rare disease business
ANI Pharmaceuticals (Nasdaq: ANIP) announced a recommended public offer to acquire Sweden-based Egetis Therapeutics, per a GlobeNewswire release. The deal would expand ANI's rare disease footprint and scale its specialty pharma business.
Source:
globenewswire.com: https://www.globenewswire.com/news-release/2026/11/05/3396047/0/en/ani-pharmaceuticals-announces-offer-to-acquire-egetis-therapeutics-expanding-the-scope-and-scale-of-its-rare-disease-business.html
Not financial advice. For informational and educational purposes only.

